CT/NIRF dual-modal imaging tracking and therapeutic efficacy of transplanted mesenchymal stem cells labeled with Au nanoparticles in silica-induced pulmonary fibrosis

Huang, Jie; Ning, Xinyu; Luo, Wei; Chen, Meng‐Ling; Wang, Zhangyan; Zhang, Wei; Zhang, Zhijun; Chao, Jie

doi:10.1039/c9tb02652e

Cited by 31 publications

(22 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bioluminescence imaging (BLI) which utilizes luciferase reactions also has the advantage of providing viability information of transplanted cells, but this method suffers from poor tissue penetration and low spatial resolution. MSCs can also be labeled with gold nanoparticle and tracked by computed tomography (CT) image in vivo [244,245]. These gold nanoparticles have advantage of exerting negligible influence on viability, proliferation, and differentiation ability of labeled MSCs, and offer good spatial resolution and long-term tracking when used in conjunction with CT modality [244].…”

Section: Methods Of Tracking Mscs In Vivomentioning

confidence: 99%

Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications

et al. 2021

View full text Add to dashboard Cite

Mesenchymal stem/stromal cells (MSCs) are a promising resource for cell-based therapy because of their high immunomodulation ability, tropism towards inflamed and injured tissues, and their easy access and isolation. Currently, there are more than 1200 registered MSC clinical trials globally. However, a lack of standardized methods to characterize cell safety, efficacy, and biodistribution dramatically hinders the progress of MSC utility in clinical practice. In this review, we summarize the current state of MSC-based cell therapy, focusing on the systemic safety and biodistribution of MSCs. MSC-associated risks of tumor initiation and promotion and the underlying mechanisms of these risks are discussed. In addition, MSC biodistribution methodology and the pharmacokinetics and pharmacodynamics of cell therapies are addressed. Better understanding of the systemic safety and biodistribution of MSCs will facilitate future clinical applications of precision medicine using stem cells.

show abstract

Section: Methods Of Tracking Mscs In Vivomentioning

confidence: 99%

Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stem cells (MSCs) have shown promising therapeutic effects on IPF [6]. In general, MSCs have therapeutic capability for repairing injured tissues by releasing extracellular vesicles (EVs) carrying various active cargoes [7].…”

Section: Introductionmentioning

confidence: 99%

microRNA-186 in extracellular vesicles from bone marrow mesenchymal stem cells alleviates idiopathic pulmonary fibrosis via interaction with SOX4 and DKK1

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Previous reports have identified that human bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) with their cargo microRNAs (miRNAs) are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis (IPF). Therefore, we explored whether delivery of microRNA-186 (miR-186), a downregulated miRNA in IPF, by BMSC EVs could interfere with the progression of IPF in a murine model. Methods In a co-culture system, we assessed whether BMSC-EVs modulated the activation of fibroblasts. We established a mouse model of PF to evaluate the in vivo therapeutic effects of BMSC-EVs and determined miR-186 expression in BMSC-EVs by polymerase chain reaction. Using a loss-of-function approach, we examined how miR-186 delivered by BMSC-EVs affected fibroblasts. The putative relationship between miR-186 and SRY-related HMG box transcription factor 4 (SOX4) was tested using luciferase assay. Next, we investigated whether EV-miR-186 affected fibroblast activation and PF by targeting SOX4 and its downstream gene, Dickkopf-1 (DKK1). Results BMSC-EVs suppressed lung fibroblast activation and delayed IPF progression in mice. miR-186 was downregulated in IPF but enriched in the BMSC-EVs. miR-186 delivered by BMSC-EVs could suppress fibroblast activation. Furthermore, miR-186 reduced the expression of SOX4, a target gene of miR-186, and hence suppressed the expression of DKK1. Finally, EV-delivered miR-186 impaired fibroblast activation and alleviated PF via downregulation of SOX4 and DKK1. Conclusion In conclusion, miR-186 delivered by BMSC-EVs suppressed SOX4 and DKK1 expression, thereby blocking fibroblast activation and ameliorating IPF, thus presenting a novel therapeutic target for IPF.

show abstract

“…Different types of NIR fluorescent NPs (such as quantum dots, rare-earth NPs, and organic fluorescent NPs) have been used for in vivo tracking of transplanted stem cells (Chen et al, 2018). It was confirmed that BMSCs labeled with AA@ICG@PLL NPs could be effectively transplanted into SiO 2 −induced PF mice, and then monitored by CT/NIR fluorescence dual-modality imaging for up to 21 days (Huang et al, 2020). Additionally, BMSCs were observed to migrate to damaged lung tissue when DiR-labeled BMSCs were transplanted into a SiO 2 −induced PF rat model (Li et al, 2018).…”

Section: Imaging-guided Therapymentioning

confidence: 94%

Recent Advances in Fluorescence Imaging of Pulmonary Fibrosis in Animal Models

Liu

Tang

Zhu

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Pulmonary fibrosis (PF) is a lung disease that may cause impaired gas exchange and respiratory failure while being difficult to treat. Rapid, sensitive, and accurate detection of lung tissue and cell changes is essential for the effective diagnosis and treatment of PF. Currently, the commonly-used high-resolution computed tomography (HRCT) imaging has been challenging to distinguish early PF from other pathological processes in the lung structure. Magnetic resonance imaging (MRI) using hyperpolarized gases is hampered by the higher cost to become a routine diagnostic tool. As a result, the development of new PF imaging technologies may be a promising solution. Here, we summarize and discuss recent advances in fluorescence imaging as a talented optical technique for the diagnosis and evaluation of PF, including collagen imaging, oxidative stress, inflammation, and PF-related biomarkers. The design strategies of the probes for fluorescence imaging (including multimodal imaging) of PF are briefly described, which can provide new ideas for the future PF-related imaging research. It is hoped that this review will promote the translation of fluorescence imaging into a clinically usable assay in PF.

show abstract

CT/NIRF dual-modal imaging tracking and therapeutic efficacy of transplanted mesenchymal stem cells labeled with Au nanoparticles in silica-induced pulmonary fibrosis

Abstract: AA@ICG@PLL NPs, as CT/NIRF dual modal nanotracers, were synthesized to track BMSCs in the treatment of pulmonary fibrosis.

Cited by 31 publications

References 59 publications

Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications

Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications

microRNA-186 in extracellular vesicles from bone marrow mesenchymal stem cells alleviates idiopathic pulmonary fibrosis via interaction with SOX4 and DKK1

Recent Advances in Fluorescence Imaging of Pulmonary Fibrosis in Animal Models

Contact Info

Product

Resources

About